Results 51 to 60 of about 2,227,737 (406)

Predictors and Prognostic Value of Worsening Renal Function During Admission in HFpEF Versus HFrEF: Data From the KorAHF (Korean Acute Heart Failure) Registry

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundWorsening renal function (WRF) is associated with adverse outcomes in patients with heart failure. We investigated the predictors and prognostic value of WRF during admission, in patients with preserved ejection fraction (HFpEF) versus those ...
Jeehoon Kang, Jin Joo Park, Young‐Jin Cho, Il‐Young Oh, Hyun‐Ah Park, Sang Eun Lee, Min‐Seok Kim, Hyun‐Jai Cho, Hae‐Young Lee, Jin Oh Choi, Kyung‐Kuk Hwang, Kye Hun Kim, Byung‐Su Yoo, Seok‐Min Kang, Sang Hong Baek, Eun‐Seok Jeon, Jae‐Joong Kim, Myeong‐Chan Cho, Shung Chull Chae, Byung‐Hee Oh, Dong‐Ju Choi   +20 more
doaj   +1 more source

Immunity, Inflammation and Heart Failure: Their Role on Cardiac Function and Iron Status [PDF]

, 2019
Aims: Heart failure is a clinical syndrome characterized by subclinical systemic inflammation and immune system activation associated with iron deficiency.
Corrao S., Gigliotti S., Greco M., Hribal M. L., Miceli S., Perticone F., Perticone M., Pinto A., Sesti G., Suraci E., Zito R.   +10 more
core   +1 more source

ST2 in heart failure with preserved and reduced ejection fraction [PDF]

Scandinavian Cardiovascular Journal, 2019
Soluble suppression of tumorigenecity 2 (sST2) is prognostic in acute and chronic heart failure with reduced ejection fraction (HFrEF) but less studied in HF with preserved EF (HFpEF). We evaluated sST2 concentrations, correlations with biomarkers and echocardiographic measures of diastolic and systolic function, and associations with outcomes in HFpEF
Jean-Claude Daubert, Ulrika Ljung Faxén, Ulrika Ljung Faxén, Camilla Hage, Camilla Hage, Cecilia Linde, Cecilia Linde, Erwan Donal, Lars H. Lund, Lars H. Lund, Emil Najjar, Emil Najjar   +11 more
openaire   +5 more sources

Classification of Heart Failure According to Ejection Fraction JACC Review Topic of the Week [PDF]

, 2021
The recent U.S. Food and Drug Administration expanded indication for sacubitril/valsartan introduces a new potential taxonomy for heart failure, with no reference to "preserved" ejection fraction but referring to "below normal" ejection fraction as those
Lam, Carolyn S. P., Solomon, Scott D.
core   +1 more source

Sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: A review

Терапевтический архив, 2023
Heart failure with mildly reduced ejection fraction and heart failure with preserved ejection fraction are associated with significant morbidity and mortality, as well as growing economic burden.
Igor V. Zhirov, Natalia V. Safronova, Sergey N. Tereshchenko   +2 more
doaj   +1 more source

WarpPINN: Cine-MR image registration with physics-informed neural networks [PDF]

, 2022
Heart failure is typically diagnosed with a global function assessment, such as ejection fraction. However, these metrics have low discriminate power, failing to distinguish different types of this disease. Quantifying local deformations in the form of cardiac strain can provide helpful information, but it remains a challenge.
arxiv   +1 more source

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

New England Journal of Medicine, 2021
BACKGROUND Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction ...
S. Anker, J. Butler, G. Filippatos, J. Ferreira, E. Bocchi, M. Böhm, H. Brunner-la Rocca, D. Choi, V. Chopra, E. Chuquiure-Valenzuela, N. Giannetti, J. Gómez-Mesa, S. Janssens, J. Januzzi, J. González-Juanatey, B. Merkely, S. Nicholls, S. Perrone, I. Piña, P. Ponikowski, M. Senni, D. Sim, J. Špinar, I. Squire, S. Taddei, H. Tsutsui, S. Verma, D. Vinereanu, Jian Zhang, P. Carson, Carolyn S. P. Lam, N. Marx, C. Zeller, N. Sattar, W. Jamal, S. Schnaidt, J. Schnee, M. Brueckmann, S. Pocock, F. Zannad, M. Packer   +40 more
semanticscholar   +1 more source

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. [PDF]

, 2021
AIMS: No therapy has shown to reduce the risk of hospitalization for heart failure across the entire range of ejection fractions seen in clinical practice. We assessed the influence of ejection fraction on the effect of the sodium-glucose cotransporter 2
Anker, Stefan D, Brueckmann, Martina, Butler, Javed, Ferreira, Joao Pedro, Filippatos, Gerasimos, Packer, Milton, Pocock, Stuart J, Schnee, Janet, Zannad, Faiez, Zeller, Cordula   +9 more
core   +2 more sources

New Classification for Heart Failure with Mildly Reduced Ejection Fraction : Greater clarity or more confusion? [PDF]

, 2017
The latest European Society of Cardiology (ESC) guidelines for the diagnosis and management of heart failure include a new patient group for those with heart failure with mildly reduced ejection fraction (HFmrEF).
Nadar, Sunil
core   +3 more sources

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction

Journal of Cardiovascular Development and Disease, 2023
Heart failure with reduced ejection fraction is a chronic and progressive syndrome that continues to be a substantial financial burden for health systems in Western countries. Despite remarkable advances in pharmacologic and device-based therapy over the
Luigi Falco, Benedetta Brescia, Dario Catapano, Maria Luigia Martucci, Fabio Valente, Rita Gravino, Carla Contaldi, Giuseppe Pacileo, Daniele Masarone   +8 more
doaj   +1 more source